Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Botanix Pharmaceuticals Limited ( (AU:BOT) ).
Botanix Pharmaceuticals has notified the market of the issue of 772,997,200 unlisted options, each exercisable at $0.06 on or before 31 January 2027, under an existing Appendix 3B transaction framework. The substantial volume of low‑priced unquoted options expands the company’s equity-based incentives and potential future capital base, which may influence ownership dilution dynamics and funding flexibility for its ongoing pharmaceutical initiatives.
The most recent analyst rating on (AU:BOT) stock is a Buy with a A$1.00 price target. To see the full list of analyst forecasts on Botanix Pharmaceuticals Limited stock, see the AU:BOT Stock Forecast page.
More about Botanix Pharmaceuticals Limited
Botanix Pharmaceuticals Ltd is an ASX-listed pharmaceutical company focused on developing and commercialising drug products. Its activities centre on therapeutics in the healthcare sector, leveraging capital markets to fund research, development and potential commercial operations.
Average Trading Volume: 15,652,456
Technical Sentiment Signal: Sell
Current Market Cap: A$94.92M
For detailed information about BOT stock, go to TipRanks’ Stock Analysis page.